Key Slides on Using HIV-ASSIST to Guide ART Selection in a Treatment-Experienced Patient With Comorbidities

Review these slides for a demonstration on the use of HIV-ASSIST―a free, online, decision-support tool―as a resource for selecting ART in a patient with HIV, comorbidities, and resistance associated mutations.
Ethel D. Weld, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.41 MB
Released: May 27, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Theratechnologies Inc.
ViiV Healthcare

Related Content

Post-hoc analysis of TANGO assessed changes in quantitative and qualitative viral load through Week 96 and inflammatory biomarkers from baseline to Week 96, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 22, 2021

Large, retrospective analysis supports the effectiveness and safety of dolutegravir-based regimens among children and adolescents, reported by Clinical Care Options (CCO) from IAS 2021

Released: July 22, 2021

Lenacapavir, in combination with an optimized background regimen, showed favorable efficacy and safety in patients with MDR HIV-1 infection from IAS 2021, as reported by Clinical Care Options (CCO).

Released: July 22, 2021

Dr Joseph Eron and Clinical Care Options (CCO): Weight gain in initial ART, GEMINI, ADVANCE trials, and more

Joseph J. Eron, Jr., MD Released: July 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue